Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Stomach Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Capecitabine , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Esophagogastric Junction/pathology , Female , Fluorouracil/administration & dosage , Fluorouracil/analogs & derivatives , Humans , Male , Middle Aged , Patient Selection , Survival Analysis , Treatment OutcomeSubject(s)
Colorectal Neoplasms/drug therapy , Medication Errors , Organoplatinum Compounds/adverse effects , Asthenia/chemically induced , Colorectal Neoplasms/pathology , Diarrhea/chemically induced , Dose-Response Relationship, Drug , Drug Overdose , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Middle Aged , Neutropenia/chemically induced , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Peripheral Nervous System Diseases/chemically induced , Recovery of Function , Thrombocytopenia/chemically induced , Treatment OutcomeSubject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Carcinoma, Basal Cell/drug therapy , Eyelid Neoplasms/drug therapy , Paclitaxel/administration & dosage , Skin Neoplasms/drug therapy , Aged , Carcinoma, Basal Cell/pathology , Eyelid Neoplasms/pathology , Humans , Male , Middle Aged , Skin Neoplasms/pathologyABSTRACT
INTRODUCTION: In an attempt to increase the dose intensity of cisplatin and gemcitabine given to patients with stage IIIB or IV nonsmall cell lung cancer without increasing toxicity, we have studied a biweekly administration schedule. We analyze the safety and efficacy of this treatment. METHODS AND PATIENTS: In this study, cycles of 50 mg/m2 cisplatin with 2500 mg/m2 gemcitabine were given on days 1 and 15 every 28 days. The median age of the 49 patients was 62 years and 23 were in stage IIIB patients (46.9%), whereas 26 (53.1%) were in stage IV. RESULTS: Overall response rate was 38.8%, 52.2% for stage IIIB and 26.9% for stage IV. Median survival was 48 weeks and 1-year survival was 44%, with 66.7% of stage IIIB patients and 13.3% of stage IV patients surviving for 1 year. In the study, 178 cycles were administered, a mean of 4 cycles per patient. The intensity of the 359 administrations reached 91.16% of the planned dosage, although 49 were delayed for 1 week while subjects recovered from the toxicity. There was 1 toxic death and 2 patients experienced vascular toxicity with distal arterial ischemic severe changes in their lower extremities. There were 7 episodes of grade 2 neutropenia, 2 of grade 3, and one of grade 4; however, no cases of febrile neutropenia were seen. The predominant nonhematologic toxic effects were asthenia and nausea/vomiting. CONCLUSION: The schedule of cisplatin and gemcitabine analyzed is active with a good therapeutic index.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Adult , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Drug Administration Schedule , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Prospective Studies , Survival Rate , GemcitabineSubject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Extravasation of Diagnostic and Therapeutic Materials/etiology , Extravasation of Diagnostic and Therapeutic Materials/pathology , Taxoids/adverse effects , Antineoplastic Agents, Phytogenic/therapeutic use , Docetaxel , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Taxoids/therapeutic useABSTRACT
Clinical systemic amyloidosis has been rarely described in patients with lung cancer. A new case of such an association is described with a review of the literature and a discussion about the possible biological mechanisms responsible for the development of systemic amyloidosis in patients with lung cancer. Circulating precursors of amyloid fibrils in patients with lung cancer might be implicated more than expected in the biology of tumoral disease.
